Innovent Biologics Unveils Promising Preclinical Study Results for Novel Antibody-Peptide Conjugate Targeting Cardiovascular Risk Markers at ADA Conference

Reuters

2025/06/22

Innovent Biologics Unveils Promising Preclinical Study Results for Novel Antibody-Peptide Conjugate Targeting Cardiovascular Risk Markers at ADA Conference

Innovent Biologics Inc. is set to present multiple research findings from its biomedicine pipeline at the upcoming American Diabetes Association's $(ADA.AU)$ 85th Scientific Sessions. Scheduled for June 22, 2025, the presentations will include exploratory mechanism-of-action analyses of mazdutide from investigator-initiated trials and a preclinical study of IBI3030, a novel PCSK9-GGG antibody-peptide conjugate. IBI3030 has shown promise in preclinical models for improving cardiovascular risk markers through its multi-target approach. The preclinical study results indicate significant reductions in LDL-c and Lp(a), improved glucose tolerance, weight reduction, and preserved insulin sensitivity. These findings will be showcased during a poster session at the ADA conference, highlighting Innovent's commitment to advancing next-generation therapies in cardiovascular and metabolic diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN15538) on June 22, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2545438805"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545438805\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2545438805?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-22 09:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545438805","market":"nz","top_or_hot":-1,"title":"Innovent Biologics Unveils Promising Preclinical Study Results for Novel Antibody-Peptide Conjugate Targeting Cardiovascular Risk Markers at ADA Conference","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Innovent Biologics Unveils Promising Preclinical Study Results for Novel Antibody-Peptide Conjugate Targeting Cardiovascular Risk Markers at ADA Conference\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics Inc.</a> is set to present multiple research findings from its biomedicine pipeline at the upcoming American Diabetes Association's <a href=\"https://laohu8.com/S/ADA.AU\">$(ADA.AU)$</a> 85th Scientific Sessions. Scheduled for June 22, 2025, the presentations will include exploratory mechanism-of-action analyses of mazdutide from investigator-initiated trials and a preclinical study of IBI3030, a novel PCSK9-GGG antibody-peptide conjugate. IBI3030 has shown promise in preclinical models for improving cardiovascular risk markers through its multi-target approach. The preclinical study results indicate significant reductions in LDL-c and Lp(a), improved glucose tolerance, weight reduction, and preserved insulin sensitivity. These findings will be showcased during a poster session at the ADA conference, highlighting Innovent's commitment to advancing next-generation therapies in cardiovascular and metabolic diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IVBXF\">Innovent Biologics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN15538) on June 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Biologics Unveils Promising Preclinical Study Results for Novel Antibody-Peptide Conjugate Targeting Cardiovascular Risk Markers at ADA Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Biologics Unveils Promising Preclinical Study Results for Novel Antibody-Peptide Conjugate Targeting Cardiovascular Risk Markers at ADA Conference\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-22 09:36</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Innovent Biologics Unveils Promising Preclinical Study Results for Novel Antibody-Peptide Conjugate Targeting Cardiovascular Risk Markers at ADA Conference\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics Inc.</a> is set to present multiple research findings from its biomedicine pipeline at the upcoming American Diabetes Association's <a href=\"https://laohu8.com/S/ADA.AU\">$(ADA.AU)$</a> 85th Scientific Sessions. Scheduled for June 22, 2025, the presentations will include exploratory mechanism-of-action analyses of mazdutide from investigator-initiated trials and a preclinical study of IBI3030, a novel PCSK9-GGG antibody-peptide conjugate. IBI3030 has shown promise in preclinical models for improving cardiovascular risk markers through its multi-target approach. The preclinical study results indicate significant reductions in LDL-c and Lp(a), improved glucose tolerance, weight reduction, and preserved insulin sensitivity. These findings will be showcased during a poster session at the ADA conference, highlighting Innovent's commitment to advancing next-generation therapies in cardiovascular and metabolic diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IVBXF\">Innovent Biologics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN15538) on June 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心資產","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250622:nNDL95NyDN:1","article_id":"2545438805","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545438805","pubTimestamp":1750556184,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Innovent Biologics Unveils Promising Preclinical Study Results for Novel Antibody-Peptide Conjugate Targeting Cardiovascular Risk Markers at ADA Conference. Innovent Biologics Inc. is set to present multiple research findings from its biomedicine pipeline at the upcoming American Diabetes Association's  85th Scientific Sessions. Scheduled for June 22, 2025, the presentations will include exploratory mechanism-of-action analyses of mazdutide from investigator-initiated trials and a preclinical study of IBI3030, a novel PCSK9-GGG antibody-peptide conjugate. IBI3030 has shown promise in preclinical models for improving cardiovascular risk markers through its multi-target approach. The preclinical study results indicate significant reductions in LDL-c and Lp, improved glucose tolerance, weight reduction, and preserved insulin sensitivity. These findings will be showcased during a poster session at the ADA conference, highlighting Innovent's commitment to advancing next-generation therapies","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1589":"北水核心资产","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1147":"投资银行业与经纪业","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1161":"生物科技","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","01911":"华兴资本控股","BK1583":"高瓴概念","01801":"信达生物"},"translate_title":"信达生物在ADA会议上公布靶向心血管风险标志物的新型抗体-肽偶联物有希望的临床前研究结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01911":0.9,"01801":0.9},"content_text":"Innovent Biologics Unveils Promising Preclinical Study Results for Novel Antibody-Peptide Conjugate Targeting Cardiovascular Risk Markers at ADA Conference\n    \n\nInnovent Biologics Inc. is set to present multiple research findings from its biomedicine pipeline at the upcoming American Diabetes Association's $(ADA.AU)$ 85th Scientific Sessions. Scheduled for June 22, 2025, the presentations will include exploratory mechanism-of-action analyses of mazdutide from investigator-initiated trials and a preclinical study of IBI3030, a novel PCSK9-GGG antibody-peptide conjugate. IBI3030 has shown promise in preclinical models for improving cardiovascular risk markers through its multi-target approach. The preclinical study results indicate significant reductions in LDL-c and Lp(a), improved glucose tolerance, weight reduction, and preserved insulin sensitivity. These findings will be showcased during a poster session at the ADA conference, highlighting Innovent's commitment to advancing next-generation therapies in cardiovascular and metabolic diseases.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN15538) on June 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}